title: Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
authors.forename: Victoria L
authors.initials: VL
authors.lastname: Vetter
authors.forename: Josephine
authors.initials: J
authors.lastname: Elia
authors.forename: Christopher
authors.initials: C
authors.lastname: Erickson
authors.forename: Stuart
authors.initials: S
authors.lastname: Berger
authors.forename: Nathan
authors.initials: N
authors.lastname: Blum
authors.forename: Karen
authors.initials: K
authors.lastname: Uzark
authors.forename: Catherine L
authors.initials: CL
authors.lastname: Webb
mesh_terms: D000293:Adolescent; D000572:American Heart Association; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D002648:Child; D006287:Health Planning Guidelines; D006330:Heart Defects, Congenital / Q000188:drug therapy / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008991:Monitoring, Physiologic / Q000592:standards; D009729:Nursing / Q000592:standards; D014481:United States
chemical_list: D000697:Central Nervous System Stimulants